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Background/aim: Reduced vitamin D is considered as one of the environmental factors that can increase the prevalence of certain
autoimmune diseases. This study aimed to assess vitamin D metabolism in patients with vitiligo.
Materials and methods: A prospective case-control study was conducted on 44 consecutive patients with vitiligo vulgaris and 43
healthy controls. Their plasma 25-hydroxyvitamin D (25(OH)D), parathormone (PTH), calcium, magnesium, and phosphate levels
were measured.
Results: There was no significant difference in the mean age, sex and Fitzpatrick skin phototype between the patient and control groups
(P > 0.05). The plasma levels of 25(OH)D and calcium were signiﬁcantly decreased (P = 0.002, P < 0.0001, respectively) and PTH and
magnesium levels were significantly increased in patients with vitiligo (P < 0.0001, P < 0.0001, respectively). The advancement of age (P
= 0.03, R = –0.18) and comorbid autoimmune illnesses (P = 0.04) were found to be significantly associated with lower 25(OH)D levels.
Conclusion: There is a universal lack of 25(OH)D in the Turkish population. Screening for vitamin D may be a tool for the presence
of comorbid autoimmune diseases. Further studies are needed to understand the role of vitamin D metabolism in the pathogenesis of
vitiligo.
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1. Introduction
Vitiligo is a common acquired depigmenting condition
of an unknown cause. Its immunopathogenesis is not
completely understood but autoimmune etiology appears
to be the most plausible (1). The relationship of vitiligo with
other autoimmune disorders, and especially its coexistence
with autoimmune thyroid diseases, has previously been
reported (2,3). Recently, many autoimmune diseases
including vitiligo have been found to be associated with
reduced vitamin D levels (4,5).
Vitamin D has been implicated as one of the
environmental factors that may trigger or exacerbate some
autoimmune disorders including inflammatory bowel
disease, multiple sclerosis, systemic lupus erythematosus,
type 1 diabetes mellitus, and rheumatoid arthritis (4,6).
Vitamin D is a fat-soluble steroid hormone that is
obtained through diet, supplements, or synthesis in the
skin upon exposure to ultraviolet (UV) B radiation.
25-Hydroxyvitamin D (25(OH)D), with a half-life of about
* Correspondence: drzennure80@yahoo.com

2 weeks, is the major circulating vitamin D metabolite,
and it is the routinely assessed as the most appropriate
indicator of vitamin D levels in humans (7–9). Vitamin
D classically regulates bone metabolism and calcium
homeostasis. The nonclassic actions of vitamin D include
regulation of cellular proliferation and differentiation,
hormone secretion, and the immune system in both innate
and adaptive immunity (4,10).
Vitiligo is an autoimmune depigmentation disorder and
topical vitamin D analogs are effective for repigmentation
(11,12). Furthermore, vitamin D is also considered to be
associated with autoimmune disorders, and therefore the
present study was designed to determine whether there is
a relationship between vitiligo and vitamin D metabolism
in comparison to healthy controls.
2. Materials and methods
This prospective case-control study consisted of patients
who had been admitted to the outpatient clinic of
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dermatology at the Keçiören Research and Training
Hospital (Ankara, Turkey) during the period of November
2011 to February 2012. In order to minimize the effect
of seasonal changes on vitamin D levels, the study was
conducted in the same winter period. All the patients
enrolled in the study were living in Ankara, located in
central Anatolia, where these months are considered to be
winter and there is a lower level of exposure to UV light.
This study was approved by the local ethics committee
and written informed consent was obtained from each
patient. A total of 44 patients with vitiligo (20 females, 24
males, mean age: 34.5 ± 16.1 years (range: 16–60 years))
and 43 control subjects (33 females, 10 males, mean age:
33.0 ± 12.6 years (range: 17 - 60 years)) were included in
the study. Vitiligo was diagnosed on the basis of clinical
findings. Healthy control subjects were recruited from
among patients who were referred to our clinic for the
treatment of nevus and had no systemic disease. In order
to minimize the differences due to dietary intake of
vitamin D, the patient and control groups were asked to
estimate the amount of dairy products eaten per day and
take notice of similar food habituation. Exclusion from
the study was applied to the patients and controls who
used any vitamin D supplements, topical vitamin D, or
calcium-phosphate modifying drugs, or having any of the
following problems: sensitivity or dairy allergy, and recent
history of phototherapy, sunscreen usage, malignancy,
hypercalcemia, hypocalcemia, hyperparathyroidism, or
functional renal or liver abnormalities. Participants in
either group with any history of smoking (current and
former smokers) were also excluded from the study.
Demographic data, duration of vitiligo and family
history of vitiligo, and personal and family history of
comorbid autoimmune disease were acquired from
patient interviews. The Fitzpatrick skin phototype, clinical
type, and affected body surface area (BSA) were assessed
through a physical examination. The clinical appearance
of vitiligo is classified into generalized (multiple scattered
lesions in a symmetrical distribution pattern) and localized
occurrence (13). Individuals with segmental vitiligo were
not included the study. The BSA of depigmentation was
divided into 2 groups: 1%–19% BSA and ≥20% BSA.
Fasting blood samples were obtained by venipuncture of
the large antecubital veins of the patients without stasis
and after 12 h of fasting. The samples were immediately
centrifuged; the plasma was separated and stored at –80
°C. In order to avoid variation, all samples were analyzed
on the same day and using the same kit. The serum 25(OH)
D level was measured by the RIA kit (25OH-VIT.D3
RIA-CT kit (Catalog No: KIP1961)). The serum calcium,
phosphate, parathormone (PTH), and magnesium levels
were measured using standard laboratory techniques.
Vitamin D deficiency is defined as 25(OH)D below 20 ng/
mL, and >30 ng / mL was considered normal (14).
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Statistical analyses were performed with SPSS 15.0
(SPSS Inc., Chicago, IL, USA). All the numerical variables
are expressed as the mean ± standard deviation (SD). The
normality of data was analyzed using a Kolmogorov–
Smirnov test. A paired sample t-test was performed for
the initial and ﬁnal values of hormonal and biochemical
data with homogeneous variability. A Wilcoxon signedranks test was used to analyze data with nonhomogeneous
variability. For the comparison of categorical variables
or percentages, we used Fisher’s exact and chi-square
tests. Differences between numeric variables were tested
with Student’s t-test or the Mann–Whitney U test and
correlation was tested with Spearman’s rank order or the
Pearson correlation coefficient. P < 0.05 was considered to
be statistically significant.
3. Results
The demographic data, characteristics of vitiligo, and
comorbid autoimmune illnesses are given in Table 1.
There was no significant difference in mean age, sex,
and Fitzpatrick skin phototype between the patient and
the control groups (P > 0.05). Of the patients, 6.8% had
localized vitiligo and 93.2% had the generalized form
of the disease. Six patients had a history of comorbid
autoimmune illnesses, 2 patients had Hashimoto
thyroiditis, 1 patient had Graves disease, and 3 patients had
type 2 diabetes mellitus. A family history of autoimmune
disorders was reported in 9.1% of the patients. The
hormonal markers and biochemical parameters are given
in Table 2. The analyses revealed that the 25(OH)D and
serum calcium levels were significantly lower (P = 0.002, P
< 0.0001, respectively) while PTH and serum magnesium
levels were significantly higher (P < 0.0001, P < 0.0001,
respectively) in the patient group than the control group.
The serum 25(OH)D concentrations were deficient (<20
ng/mL) in 32 (72.7%) of the patient group, while in the
control group 13 (30.23%) of the subjects had 25(OH)D
deficiency (P = 0.001).
We found that advancement of age (P = 0.03, R =
–0.18) and comorbid autoimmune illnesses (P = 0.041)
were significantly associated with lower 25(OH)D levels.
We did not observe a statistically significant correlation
between vitamin D levels and sex, the clinical type of
the vitiligo, percentage of the affected BSA, duration of
the vitiligo, family history of vitiligo, or family history of
autoimmune diseases in the patient group (P > 0.05).
4. Discussion
To the best of our knowledge, this is the first study
investigating vitamin D metabolism including not only the
vitamin D level but also the PTH, calcium, magnesium,
and phosphate levels of patients with vitiligo in comparison
with healthy controls. We found that calcium and 25(OH)
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Table 1. Demographics of study subjects, characteristics of vitiligo, and comorbid
autoimmune illnesses.

Number of subjects

%

Mean age, years

37.5 ± 16.1

Sex

Male
Female

24
20

54.5
45.5

Fitzpatrick skin type
II
III

16
28

36.3
63.7

Duration of disease (months)
Mean ± SD

38.8 ± 59.1

Type

Localized
Generalized

3
41

6.8
93.2

Body surface area
1%–19%
≥20%

35
9

79.6
20.4

Family history

4

9.1

Comorbid autoimmune illness
Negative
Positive
Hashimoto disease
Graves
Diabetes mellitus

39
6
2
1
3

88.6
13.6
4.5
2.4
6.8

Family autoimmune history
Negative
Positive

40
4

90.9
9.1

Table 2. Comparison of hormonal and biochemical parameters between patients and control
group.

Patients

Controls

P

25(OH)D (ng/mL)

16.35 ± 7.41

23.98 ± 13.5

0.002

PTH (pg/mL)

98.69 ± 41.23

58.65 ± 24.17

0.0001

Calcium (mg/dL)

9.36 ± 0.37

9.84 ± 0.39

0.0001

Phosphate (mg/dL)

3.15 ± 0.69

3.36 ± 0.48

0.10

Magnesium (mmol/L)

2.1 ± 0.13

0.80 ± 0.1

0.0001

25(OH)D, 25 hydroxyvitamin D; PTH, parathormone.

D levels decreased signiﬁcantly while the PTH and
magnesium levels were significantly increased in patients
with vitiligo. We also observed that advancement of age
and comorbid autoimmune illnesses were significantly
associated with lower 25(OH)D levels in patients with
vitiligo.

Vitamin D deficiency was found in both the patients
and the controls. Hekimsoy et al. measured serum levels
of 25(OH)D of adults in the Aegean region of Turkey and
found a high prevalence of vitamin D deficiency (15). Van
der Meer et al. demonstrated that the vitamin D status in
the Turkish population varied widely in Turkey, according
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to darker skin colors, sunscreen usage, insufficient intake
of vitamin D in the diet, and the habit of using clothing to
cover most of the body (16). In addition to these factors,
in the present study, the low levels of vitamin D may be
related to the time at which blood samples were collected,
since all of the subjects were enrolled in the study in winter.
Accumulating data give rise to a link with vitamin D
in the etiopathogenesis of vitiligo. Vitamin D exerts its
effects through the nuclear vitamin D receptor (VDR).
There are studies showing an association between VDR
gene polymorphisms and vitiligo that avoids the increased
risk for developing vitiligo (17,18). Saleh et al. detected
highly significant 25(OH)D deficiency in patients with
vitiligo when compared to healthy controls (19). However,
they did not observe any significant correlation between
associated autoimmune diseases and the serum 25(OH)D
levels of patients. Xu et al. investigated the serum 25(OH)
D deficiency in Chinese patients with vitiligo (20). Their
data did not reveal a correlation between vitamin D levels
and onset of vitiligo. On the other hand, they demonstrated
that patients with vitamin D deficiency were at an
increased risk of developing autoimmune diseases. In the
study by Silverberg et al., 55.6% of the patients with vitiligo
had insufficient (<30 ng/mL) and 13.3% had very low (<15
ng/mL) vitamin D levels (5). They found that comorbid
autoimmune illness in subjects was associated with very
low 25(OH)D levels, suggesting that vitamin D levels in
patients with vitiligo may help to determine if additional
testing for other autoimmune diseases is warranted.
In the present study, serum 25(OH)D concentrations
were significantly deficient (72.7% of the patient group)
in vitiligo patients when compared to healthy controls
and comorbid autoimmune illnesses were significantly
associated with lower 25(OH)D levels in patients with
vitiligo, supporting the findings of Silverberg et al.
In this study, we found significantly higher magnesium
levels in the vitiligo group. This finding may be a mere
stimulation of magnesium reabsorption in the renal
tubule, absorption in the gut, and release of the ion from
bone by the hyperproduction of parathormone due to
vitamin D deficiency (21).
The exact cause of melanocyte loss in vitiligo is
still debatable. It is considered to be the result of an
autoimmune-mediated process, including both humoral
(circulating antibodies targeting melanocyte antigens) and
cellular immune aberrations leading to the destruction of
melanocytes. Vitiligo is associated with overproduction
of proinflammatory cytokines such as TNF-α, IL-6, and
IL-2 (22). A less traditional function of vitamin D has
been demonstrated as immunoregulation, including
the regulation and differentiation of the cells of both
the innate and adaptive immune systems (23,24). Active
vitamin D has multiple immunosuppressant properties
that inhibit the adaptive immune response by suppressing
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the proinflammatory processes (25). It has been shown
to inhibit the differentiation and maturation of myeloid
dendritic cells, and to suppress the antigen-presenting
capacity of macrophages and dendritic cells. It also has
antiproliferative effects on B and T cells and inhibits
production of several proinflammatory cytokines such
as IL-2, interferon-γ, and TNF-α of Th1 cells, known
to be associated with vitiligo (4,10,26–28). Vitamin D
compounds might limit the melanocyte loss in vitiligo
by counteracting the local immune process in the skin,
oxidative stress, programmed cell death, and aberrant
calcium fluxes and by photoprotecting the epidermal
melanin unit (28). In addition, vitamin D may stimulate
the differentiation of immature melanocyte precursors
and regulate melanocyte development and melanogenesis
(29).
Vitamin D deficiency has been shown to facilitate the
progression of existing autoimmune disease (30). The exact
mechanism by which vitamin D affects autoimmunity is
still unknown. It is a challenging question as to whether
low 25(OH)D levels are the consequence or the cause
of autoimmune disease. A further question is whether
the low 25(OH)D levels in patients with vitiligo make
subjects more susceptible to secondary autoimmunity, or
whether vitamin D deficiency is a contributory cause of
autoimmune inflammation.
Given the importance of vitamin D for a functional
immune system and the profound deficiency observed in
autoimmune diseases, as well as the correlation of vitamin
D deficiency with the disease activity, the question arises
as to whether the cells’ immunity in autoimmune diseases
are capable of responding appropriately to vitamin D.
Prospective epidemiologic data on vitamin D intake and
the risks of developing autoimmune diseases such as
rheumatoid arthritis, systemic lupus erythematosus, type 1
diabetes mellitus, and multiple sclerosis have been studied
(31–33). However, given the small number of studies, no
conclusions can be drawn.
However, as the pathogenesis of autoimmune diseases
per se is still unclear, many of the molecular pathways
suggest a potential role of vitamin D insufficiency in the
progression of vitiligo. Furthermore, the mechanisms
by which the deficiency of vitamin D triggers the
autoimmune process are not fully elucidated. In addition
to the previously reported data in the literature, our study
revealed an altered vitamin D metabolism (significant
decrease of 25(OH)D and calcium levels and significant
elevation of PTH and magnesium levels) in patients with
vitiligo. In this study, comorbid autoimmune illnesses were
also significantly associated with lower 25(OH)D levels in
patients with vitiligo. Further interventional studies are
needed to understand the role of vitamin D metabolism in
the pathogenesis of vitiligo and autoimmunity.
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